Navigation Links
Morphotek(R), Inc. and Eisai Corporation of North America Announce FDA Special Protocol Assessment (SPA) for Phase III Trial Evaluating Farletuzumab in Relapsed Ovarian Cancer
Date:3/23/2009

ebo-controlled trial. Morphotek expects to enroll up to 900 subjects in this clinical study that will be conducted globally at sites in North America, South America, Europe, Australia and Asia.

"Ovarian cancer is a disease that is devastating to the lives of patients and caregivers," said Nicholas Nicolaides, Ph.D., President and Chief Executive Officer at Morphotek. "The agreement reached in the SPA process for farletuzumab's Phase III trial may bring us one step closer to providing hope in their lives and further exemplifies our human health care (hhc) mission to bring treatments to the people who need them most."

Farletuzumab is a monoclonal antibody that binds to and blocks the function of folate receptor alpha (FRA), a cell surface protein on tumor cells that confers a growth advantage to tumorigenic cells in vitro. FRA has been demonstrated by several independent studies to be expressed on ovarian cancer cells. Preclinical data support the theory that farletuzumab achieves its pharmacological effect by two mechanisms: first, by the capacity of farletuzumab to block signaling inside cancer cells and, second, by stimulating the patient's immune system to attack and destroy the FRA positive-tumor cells. The pre-cursor to farletuzumab was originally developed by Dr. Lloyd Old at the Ludwig Institute for Cancer Research applying his pioneering work that employed whole cell immunization of tumors to identify cell surface factors. These efforts led to the development of a panel of novel antibodies that can recognize tumor cell surface antigens as well as tumor stromal cell surface antigens. Morphotek licensed the antibody and improved it using the company's proprietary morphogenics technology.

Ovarian cancer, which ranks fifth as the cause of cancer deaths in women, usually grows asymptomatically before it is discovered. The National Cancer Institute estimates that there were 21,650 new cases of ovarian
'/>"/>

SOURCE Morphotek, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Eisai Corporation of North America Announces Appointment of Vice President of U.S. Corporate Communications
2. Eisai Inc. and the Alzheimers Association Introduce the C.A.R.E. Pharmacy Award and Call for Nominations
3. Eisai Renews Its Commitment to Responsible Healthcare Community Interactions in Accordance with the Revised PhRMA Marketing Code
4. Eisai Inc. Supports Acting Surgeon Generals Call to Action to Prevent Deep Vein Thrombosis and Pulmonary Embolism
5. Biologic Drugs, Particularly Centocor/Janssen-Cilags Stelara and Abbott/Eisais Humira, will Drive the Psoriasis Drug Market to $5 Billion by 2017
6. Eisai Will Initiate First Head-to-Head Study Comparing Dacogen(R) (decitabine for injection) and Vidaza(R) (azacitidine) in Patients with Myelodysplastic Syndromes
7. Eisai Inc. and the North American Thrombosis Forum (NATF)* Introduce the DVTeamCare(TM) Hospital Award and Call for Nominations
8. Eisai and Bial Announce Partnership Agreement for the European Commercialisation of the Novel Once Daily Anti-Epileptic Zebinix(R)
9. Teikoku Pharma USA and Eisai Co., Ltd. Announce Licensing Agreement for a New 7-Day Transdermal Formulation of Donepezil.
10. The ScottCare Corporation Completes Acquisition of Rozinn Electronics, a Leading Manufacturer of Cardiac Diagnostic Products
11. Brooke Franchise Corporation Announces Selected July Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... West Hollywood, California (PRWEB) January 22, 2015 The ... 22, 2015 at 10 a.m., to commemorate the 42nd anniversary of ... the United States. , “It’s been 42 years since the Roe ... to choose is still as present as ever,” said City of ...
(Date:1/22/2015)... Padre Murphy's and Owner Tom Boyle in Glendale, AZ ... Alliance (PPHA). The PPHA's passion for others' well-being and ... greats, treated for obstructive sleep apnea (OSA) has propelled them ... in the valley. The most recent plans for an event ...
(Date:1/22/2015)... 2015 Angelweddingdress is a famous wedding dress ... customers to follow it on Facebook, Twitter, and Pinterest. The ... gift. Angelweddingdress draws a lottery every week. , Moreover, the ... 28, 2015. Click Angelweddingdress homepage for more information. ...
(Date:1/22/2015)... January 22, 2015 The federal court overseeing ... U.S. District Court, Southern District of West Virginia has upheld ... that proceeding’s first bellwether trial. In an Order dated January ... trial after finding that C.R. Bard had not proven a ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 Thousand of ... Medical Care recalled its GranuFlo and NaturaLyte dialysis concentrates ... underway in U.S. District Court, District of Massachusetts, Bernstein ... 20th, the Court has remanded a case filed by ...
Breaking Medicine News(10 mins):Health News:Padre Murphy's Holds NFL Retired Players Association Party Star Studded Event With Bud Light and Pro Player Health Alliance Sponsoring 2Health News:Padre Murphy's Holds NFL Retired Players Association Party Star Studded Event With Bud Light and Pro Player Health Alliance Sponsoring 3Health News:Angelweddingdress Invites Its Customers To Follow It On Facebook, Twitter, And Pinterest 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 3Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 4Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 3Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 4
... on November 14 in order to create awareness related to Diabetes, which ... problem with insulin, and has reached epidemic proportions. // , ... part of the World Diabetes Day, a walk is being organized in ... IMA hall, Panagal road and end at the Government Rajaji Hospital auditorium. ...
... in attention plays an important role in the onset ... of Alzheimer's disease find it more difficult to shift ... , ,The study, published in the recent issue ... require the shifting of attention, such as driving a ...
... a very famous saying which refers to an attitude when ... it and so feign that we are not concerned about ... knows it's good; yet many people still avoid it, forgoing ... statement researchers at the University of Illinois at Urbana-Champaign who ...
... a new simple test that measures the eye movement of ... Fetal Alcohol Spectrum Disorder (FASD) which would be useful in ... symptoms//. ,"Having a set of tests that can ... all of the other behavioural disorders classified under the broader ...
... on Macroeconomics and Health, K Sujatha Rao, emphasized the ... comprehensive Universal Health Insurance System for the people//. ... the GDP on health and adopt a cross-sectoral approach ... basic infrastructural needs. ,Inaugurating the two-day National Conference ...
... Goals Memorandum signed between 189 countries from Developed and ... conditions to people in poor countries have not attained ... had been reported in the Journal British Medical Journal//. ... progress on the strategy aims - the Millennium Development ...
Cached Medicine News:Health News:Doctors take part in walk: a step towards creating diabetes awareness , , 2Health News:Attention Breakdown Is The Harbinger Of Alzheimer's Disease 2Health News:Important parameters of life: Longevity and quality: both improved by exercise 2Health News:Important parameters of life: Longevity and quality: both improved by exercise 3Health News:Simple Eye Movement Test For Early Detection Of Fetal Alcohol Spectrum Disorder 2Health News:Need For Social Churning Emphasized In CMC Meet On ‘Leadership In Healthcare 2Health News:Programs for development of health in poor countries not effective 2
(Date:1/23/2015)... Ala. , Jan. 23, 2015 Gem Pharmaceuticals ... patients have been enrolled into the Company,s Phase 2 ... and safety of Gem,s lead compound, GPX-150 (an investigational ... advanced or metastatic disease. Logo - ...
(Date:1/23/2015)... Jan. 23, 2015 Tianyin Pharmaceutical Inc. (NYSE Amex: ... in the development and sale of patented biopharmaceutical medicine, ... pharmaceutical ingredients (API) today announced the business and development ... 1. Following the September 2014 JCM application ...
(Date:1/22/2015)... BOULDER, Colo. , Jan. 22, 2015  BiOptix is ... Klakamp as Vice President of Chemistry and Biochemistry. Scott ... Takeda Pharmaceuticals, AstraZeneca Pharmaceuticals, and Amgen throughout the course ... and development. "Scott is a nationally recognized ...
Breaking Medicine Technology:Gem Pharmaceuticals Announces Enrollment of Initial Patients in its Phase 2 Clinical Trial to Assess the Efficacy and Safety of GPX-150 in Sarcoma Patients 2TPI's JCM Updates on Import Registration for International Clients 2TPI's JCM Updates on Import Registration for International Clients 3TPI's JCM Updates on Import Registration for International Clients 4BiOptix Expands Leadership Team with the Appointment of Dr. Scott Klakamp as Vice President of Chemistry and Biochemistry 2
... Md. , April 27 The U.S. Food and Drug Administration ... and persistent asthma in certain adults. , ... (Logo: http://www.newscom.com/cgi-bin/prnh/20090824/FDALOGO ) , , ... Bronchial Thermoplasty System is intended for patients ages 18 and older whose severe ...
... (NYSE: CFN ) today announced plans to release third quarter results for ... on the New York Stock Exchange. , , ... will host a webcast and conference call on May 6 at ... results for its third quarter, ended on March 31, 2010 . To access ...
Cached Medicine Technology:FDA Approves New Device for Adults with Severe and Persistent Asthma 2FDA Approves New Device for Adults with Severe and Persistent Asthma 3CareFusion Will Host an Earnings Conference Call on May 6 to Discuss the Results for the Third Quarter of Fiscal 2010 2
... Durable ergonomic chairs with concave seats ... • Select options like seats, backrests, ... Choose the BE Series for top ... including: industry, education, laboratory, clean room, ...
... Durable ergonomic chairs with concave ... support • Select options like seats, ... • Choose the BE Series for ... environments including: industry, education, laboratory, clean ...
... Durable ergonomic chairs with concave seats ... • Select options like seats, backrests, ... Choose the BE Series for top ... including: industry, education, laboratory, clean room, ...
... ergonomic chairs with concave seats and ... Select options like seats, backrests, armrests, ... the BE Series for top performance ... industry, education, laboratory, clean room, static ...
Medicine Products: